教育经历

1996-1999年博士英国剑桥大学

1989-1992年硕士南京农业大学

工作经历

2011- 至 今 教授 www.优德88.cpm 唐仲英血液学研究中心

2016-2017年 访问学者 德国马谱分子生物医学研究所

2016-2016年 访问学者 韩国科学技术研究院（KAIST, Center for Vascular Research / IBS)

2005-2011年 教授 南京大学模式动物研究所

2000-2005年博士后/研究员芬兰赫尔辛基大学 Biomedicum Helsinki

1999-2000年博士后英国剑桥大学病理系

1996-1996年访问学者英国剑桥大学 妇产科系（分子生殖生物学研究室）

1994-1996年助教南京农业大学 动物科学系

1992-1994年 南京农业大学（参加江苏省委组织的社教与扶贫工作队，江苏省沭阳县）

研究领域

1.淋巴管与血管生物学

动静脉分化涉及血管内皮细胞身份确定与严格调控的血管新生过程，是心血管系统发生与重塑的关键环节；哺乳类动物的淋巴管源于静脉，胚胎发育过程中部分主静脉内皮细胞分化成淋巴管内皮细胞并逐步发育形成淋巴管系统。本研究小组主要针对受体酪氨酸激酶包括VEGFR3、Tie2及Tie1等基因，制备了多种转基因与基因敲除小鼠模型，用于研究相关信号途径在淋巴管与血管生成、网络稳态维持、瓣膜发生与功能、以及病理性重塑等过程中的作用与机制。

2. 肿瘤生物学

肿瘤转移是癌症病人死亡的主要原因，阐述肿瘤转移的机制具有重要的科学意义与临床价值。利用遗传改造小鼠模型，包括针对受体酪氨酸激酶的条件性基因敲除，结合生物发光体内成像系统及重组病毒载体介导的基因治疗，系统分析肿瘤扩散与转移灶建立过程的分子与细胞生物学机制，并筛选肿瘤组织中淋巴管与血管的特异性分子标志物，为建立肿瘤早期诊断的方法及研制抗肿瘤淋巴管与血管生长的新方法提供实验依据。

研究人员

曹旭东博士，博士后研究员	李桃桃博士，博士后研究员

研究生

博士研究生:

孙志亮	徐蓓蓓

硕士研究生:

崔静	刘亚会	李俊达	丁凯
沈昕	虞鑫豪	贾曦文

本科生:金瑜娜；王晓萌；杨香凝；凌苏安；刘哲；周显知；齐柯越

代表性论文

1. Cao Xi#, Li Ti#, Xu Bi#, Ding K, Li W, Shen B, Chu M, Zhu D, Rui L, Shang Z, Li X, Wang Y, Zheng S, Alitalo K, Liu G, Tang J, Kubota Y,He Y*. Endothelial TIE1 restricts angiogenic sprouting to coordinate vein assembly in synergy with its homologue TIE2.ATVB (Arterioscler Thromb Vasc Biol)2023 Jun 15. doi: 10.1161/ATVBAHA.122.318860. bioRxiv; DOI: 10.1101/2022.08.05.502976.

主要发现：揭示受体酪氨酸激酶TIE1、TIE2与转录因子COUPTFII存在正反馈调控回路，通过限制血管新生协同调控静脉的发生。

2. Haijuan Jiang#, Luqing Zhang#, Xuelian Liu#, Wei Sun, Katsuhiro Kato, Chuankai Chen, Xiao Li, Taotao Li, Zhiliang Sun, Wencan Han, Fujing Zhang, Qi Xiao, Zhongzhou Yang, Junhao Hu, Zhihai Qin, Ralf H. Adams, Xiang Gao,Yulong He*. Angiocrine FSTL1 (Follistatin-Like Protein 1) Insufficiency Leads to Atrial and Venous Wall Fibrosis via SMAD3 Activation.ATVB(Arterioscler Thromb Vasc Biol) 2020. doi：10.1161/ATVBAHA.119.313901. bioRxiv 616623; doi: https://doi.org/10.1101/616623.

主要发现：揭示卵泡抑制素样因子1(FSTL1)不足诱发TGFb-SMAD3信号异常激活，导致心血管系统特别是静脉纤维化病变。

3. Chu M#, Li T#, Shen B, Cao X, Zhong H, Zhang L, Zhou F, Ma W, Jiang H, Xie P, Liu Z, Dong N, Xu Y, Zhao Y, Xu G, Lu P, Luo J, Wu Q, Alitalo K, Koh GY, Adams RH,He Y*. Angiopoietin receptor Tie2 is required for vein specification and maintenance via regulating COUP-TFII.Elife. 2016 Dec 22;5. pii: e21032. doi: 10.7554/eLife.21032.

主要发现：揭示受体酪氨酸激酶TIE2-AKT介导的信号途径通过调节转录因子COUPTFII蛋白稳定性在静脉特化中的决定性作用。

4. Shen B#, Shang Z#, Wang B#, Zhang L#, Zhou F#, Li T, Chu M, Jiang H, Wang Y, Qiao T, Zhang J, Sun W, Kong X,He Y*. Genetic dissection of TIE pathway in lymphatic maturation and valve development.ATVB(Arterioscler Thromb Vasc Biol)34:1221-1230 (2014).

主要发现：揭示受体酪氨酸激酶TIE1与血管生成素ANGPT2在淋巴管成熟重塑包括集合淋巴管生成与瓣膜发生中发挥关键作用。

5. Zhang L#, Zhou F#, Han W#, Shen B, Luo J, Shibuya M,He Y*. VEGFR-3 ligand-binding and kinase activity are required for lymphangiogenesis but not for angiogenesis.Cell Res20:1319-31 (2010)-Cover paper.

主要发现：结合遗传改造小鼠模型，解析VEGFR3(血管内皮细胞生长因子受体3）配体结合域与激酶域在淋巴管与血管生成调控中的不同作用，揭示VEGFR3通过限制VEGFR2激活在血管新生过程中发挥关键作用。

6. Holopainen T#, Huang H#, Chen C#, Kim KE, Zhang L, Zhou F, Han W, Li C, Yu J, Wu J, Koh GY, Alitalo K*,He Y*. Angiopoietin-1 overexpression modulates vascular endothelium to facilitate tumor cell dissemination and metastasis establishment.Cancer Res69:4656-64 (2009).

主要发现：结合小鼠肿瘤模型，揭示血管生成素ANGPT1通过重塑血管促进肿瘤转移，阻断其受体TIE2介导的信号可显著抑制肿瘤淋巴道与血道转移。

7.He Y, Rajantie I, Pajusola K, Jeltsch M, Holopainen T, Yla-Herttuala S, Harding T, Jooss K, Takahashi T, Alitalo K. VEGFR-3 mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels.Cancer Res65:4739-46(2005).

主要发现：揭示VEGFR3(血管内皮细胞生长因子受体3）通过调控淋巴管新生促进肿瘤入侵淋巴管、并诱导其管径增加促进肿瘤淋巴道转移。

8.He Y#, Rajantie I#, Ilmonen M, Makinen T, Karkkainen MJ, Haiko P, Salven P, Alitalo K. Preexisting lymphatic endothelium but not endothelial progenitor cells are essential for tumor lymphangiogenesis and lymphatic metastasis.Cancer Res64:3737-40 (2004).

主要发现：揭示肿瘤淋巴管生成过程中淋巴管内皮细胞主要来源于周围正常组织中已存在的淋巴管。

9.He Y, Kozaki K, Karpanen T, Koshikawa K, Yla-Herttuala S, Takahashi T, Alitalo K. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling.J Natl Cancer Inst94:785-7 (2002).

主要发现：首次在小鼠肿瘤模型中证实，抑制VEGFR3(血管内皮细胞生长因子受体3）介导的信号途径可阻断肿瘤淋巴道转移，为抗肿瘤临床研究与药物研发提供了重要的实验依据。

10.He Y*, Smith SK, Day KA, Clark D, Licence DR, Charnock-Jones DS*. Alternative splicing of vascular endothelial growth factor (VEGF)-R1 (FLT-1) pre-mRNA is important for the regulation of VEGF activity.Mol Endocrinol13:537-545 (1999).

主要发现：揭示胎盘滋养层细胞通过调控血管内皮细胞生长因子受体1（VEGFR1，也称为FLT1）前信使RNA不同剪接表达可溶性受体(sFLT1)从而调控VEGFA的生物活性。

发表论文

*corresponging author, #co-first author

48. Taotao Li#, Xudong Cao#, Fei Zhou#, Jing Cui, Beibei Xu, Xiujuan Li, Lena Claesson-Welsh, Taija Makinen,Yulong He*. A critical role of VEGFR2 in lymphatic tumor metastasis.bioRxiv; 2023. doi: 10.1101/2023.02.16.528814.

47. Cao Xi#, Li Ti#, Xu Bi#, Ding K, Li W, Shen B, Chu M, Zhu D, Rui L, Shang Z, Li X, Wang Y, Zheng S, Alitalo K, Liu G, Tang J, Kubota Y,He Y*. Endothelial TIE1 restricts angiogenic sprouting to coordinate vein assembly in synergy with its homologue TIE2.ATVB (Arterioscler Thromb Vasc Biol)2023 Jun 15. doi: 10.1161/ATVBAHA.122.318860. bioRxiv; DOI: 10.1101/2022.08.05.502976.

46. Wang W, Li X, Ding X, Xiong S, Hu Z, Lu X, Zhang K, Zhang H, Hu Q, Lai KS, Chen Z, Yang J, Song H, Wang Y, Wei L, Xia Z, Zhou B,He Y, Pu J, Liu X, Ke R, Wu T, Huang C, Baldini A, Zhang M, Zhang Z. Lymphatic endothelial transcription factor Tbx1 promotes an immunosuppressive microenvironment to facilitate post-myocardial infarction repair.Immunity. 2023 Aug 15:S1074-7613(23)00332-1. doi: 10.1016/j.immuni.2023.07.019.

45. Liu X, Han M, Weng W, Li Y, Pu W, Liu K, Li X, He L, Sun R, Shen R,He Y, Liang D, Chen YH, Wang QD, Tchorz JS, Zhou B. Functional ProTracer identifies patterns of cell proliferation in tissues and underlying regulatory mechanisms.NPJ Regen Med. 2023 Aug 3;8(1):41. doi: 10.1038/s41536-023-00318-y.

44. Yuan N, Wei W, Ji L, Qian J, Jin Z, Liu H, Xu L, Li L, Zhao C, Gao X,He Y, Wang M, Tang L, Fang Y, Wang J. Young donor hematopoietic stem cells revitalize aged or damaged bone marrow niche by transdifferentiating into functional niche cells.Aging Cell. 2023 May 24:e13889. doi: 10.1111/acel.13889.

43. Qi L, Li X, Zhang F, Zhu X, Zhao Q, Yang D, Hao S, Li T, Li X, Tian T, Feng J, Sun X, Wang X, Gao S, Wang H, Ye J, Cao S,He Y, Wang H, Wei B. VEGFR-3 signaling restrains the neuron-macrophage crosstalk during neurotropic viral infection.Cell Rep. 2023 May 10;42(5):112489. doi: 10.1016/j.celrep.2023.112489.

42. Passardi A, Bittoni A, Bai Z, Zhang Z, Sier C,He Y, Shahini E, Solimando AG. Editorial: Angiogenesis blockade for the treatment of gastrointestinal cancer.Front Oncol. 2023;13:1147849. doi: 10.3389/fonc.2023.1147849.

41. Ma W, Wan Y, Zhang J, Yao J, Wang Y, Lu J, Liu H, Huang X, Zhang X, Zhou H,He Y, Wu D, Wang J, Zhao Y. Growth arrest-specific protein 2 (GAS2) interacts with CXCR4 to promote T-cell leukemogenesis partially via c-MYC.Mol Oncol. 2022 Oct;16(20):3720-3734. doi: 10.1002/1878-0261.13306.

40. Korhonen EA, Murtomäki A, Jha SK, Anisimov A, Pink A, Zhang Y, Stritt S, Liaqat I, Stanczuk L, Alderfer L, Sun Z, Kapiainen E, Singh A, Sultan I, Lantta A, Leppänen VM, Eklund L,He Y, Augustin HG, Vaahtomeri K, Saharinen P, Mäkinen T, Alitalo K. Lymphangiogenesis requires Ang2/Tie/PI3K signaling for VEGFR3 cell-surface expression.J Clin Invest. 2022 Aug 1;132(15):e155478. doi: 10.1172/JCI155478.

39. Yang Y, Xiao Q, Yin J, Li C, Yu D,He Y, Yang Z, Wang G. Med23 supports angiogenesis and maintains vascular integrity through negative regulation of angiopoietin2 expression.Commun Biol. 2022 Apr 19;5(1):374. doi: 10.1038/s42003-022-03332-w.

38. Ma L, Li W, Zhang Y, Qi L, Zhao Q, Li N, Lu Y, Zhang L, Zhou F, Wu Y, He Y, Yu H,He Y*, Wei B*, Wang H*. FLT4/VEGFR3 activates AMPK to coordinate glycometabolic reprogramming with autophagy and inflammasome activation for bacterial elimination.Autophagy. 2022; 18(6): 1385–1400. doi: 10.1080/15548627.2021.1985338

37. Cao X#, Xu B#, Li X#, Li T andHe Y*. A Genetically engineered mouse model of venous anomaly and retinal angioma-like vascular malformation.Bio-protocol2021 11(15): e4117. DOI: 10.21769/BioProtoc.4117.

36. Gan Y, Zhang T, Chen X, Cao W, Lin L, Du L, Wang Y, Zhou F, He X,He Y, Gan J, Sheng H, Sorokin L, Shi Y, Wang Y. Steroids Enable Mesenchymal Stromal Cells to Promote CD8+ T Cell Proliferation Via VEGF-C.Adv Sci(Weinh). 2021 May 2;8(12):2003712. doi: 10.1002/advs.202003712

35. Bae H, Hong KY, Lee CK, Jang C, Lee SJ, Choe K, Offermanns S,He Y*, Lee HJ, Koh GY*. Angiopoietin-2-integrin α5β1 signaling enhances vascular fatty acid transport and prevents ectopic lipid-induced insulin resistance.Nat Commun. 2020 Jun 12;11(1):2980. doi: 10.1038/s41467-020-16795-4.

34. Haijuan Jiang#, Luqing Zhang#, Xuelian Liu#, Wei Sun, Katsuhiro Kato, Chuankai Chen, Xiao Li, Taotao Li, Zhiliang Sun, Wencan Han, Fujing Zhang, Qi Xiao, Zhongzhou Yang, Junhao Hu, Zhihai Qin, Ralf H. Adams, Xiang Gao,Yulong He*. Angiocrine FSTL1 (Follistatin-Like Protein 1) Insufficiency Leads to Atrial and Venous Wall Fibrosis via SMAD3 Activation.ATVB(Arterioscler Thromb Vasc Biol) 2020. doi：10.1161/ATVBAHA.119.313901. bioRxiv 616623; doi: https://doi.org/10.1101/616623.

33. Hu X, Deng Q, Ma L, Li Q, Chen Y, Liao Y, Zhou F, Zhang C, Shao L, Feng J, He T, Ning W, Kong Y, Huo Y, He A, Liu B, Zhang J, Adams R,He Y, Tang F, Bian X, Luo J. Meningeal lymphatic vessels regulate brain tumor drainage and immunity.Cell Res2020 30: 229-243. doi: 10.1038/s41422-020-0287-8.

32.He Y*. Angiopoietins and TIE Receptors in Lymphangiogenesis and Tumor Metastasis. In: Marmé D. (eds)Tumor Angiogenesis- A Key Target for Cancer Therapy. 2019 Springer, Cham. https://link.springer.com/referencework/10.1007/978-3-319-31215-6.

31. Zheng Y; Liu C; Li Y; Jiang H; Yang P; Tang J; Xu Y; Wang H;He Y*. Loss-of-function mutations with circadian rhythm regulator Per1/Per2 lead to premature ovarian insufficiency.Biol Reprod.2019 Apr 1;100(4):1066-1072. doi:10.1093/biolre/ioy245.

30. Lee SJ, Lee CK, Kang S, Park I, Kim YH, Kim SK, Hong SP, Bae H,He Y, Kubota Y, Koh GY. Angiopoietin-2 exacerbates cardiac hypoxia and inflammation after myocardial infarction.J Clin Invest.2018 Nov 1;128(11):5018-5033. doi: 10.1172/JCI99659. Epub 2018 Oct 8.

29. Li P, Wei G, Cao Y, Deng Q, Han X, Huang X, Huo Y,He Y, Chen L, Luo J. Myosin IIa is critical for cAMP-mediated endothelial secretion of von Willebrand factor.Blood2018 131:686-698. doi: 10.1182/blood-2017-08-802140. Epub 2017 Dec 5

28. Kim J, Park DY, Bae H, Park DY, Kim D, Lee CK, Song S, Chung TY, Lim DH, Kubota Y, Hong YK,He Y, Augustin HG, Oliver G, Koh GY. Impaired angiopoietin/Tie2 signaling compromises Schlemm's canal integrity and induces glaucoma.J Clin Invest. 2017 Oct 2;127(10):3877-3896. doi: 10.1172/JCI94668. Epub 2017 Sep 18.

27. Park DY, Lee J, Kim J, Kim K, Hong S, Han S, Kubota Y, Augustin HG, Ding L, Kim JW, Kim H,He Y, Adams RH, Koh GY. Plastic roles of pericytes in the blood-retinal barrier.Nat Commun. 2017 May 16;8:15296. doi: 10.1038/ncomms15296.

26.何玉龙*，朱元贵，李伯良，董尔丹*，淋巴管系统相关研究现状与展望，科学通报，2017，62（10）：1030-1040.

25. Chu M#, Li T#, Shen B, Cao X, Zhong H, Zhang L, Zhou F, Ma W, Jiang H, Xie P, Liu Z, Dong N, Xu Y, Zhao Y, Xu G, Lu P, Luo J, Wu Q, Alitalo K, Koh GY, Adams RH,He Y*. Angiopoietin receptor Tie2 is required for vein specification and maintenance via regulating COUP-TFII.Elife. 2016 Dec 22;5. pii: e21032. doi: 10.7554/eLife.21032.

24. Chen L, Li J, Wang F, Dai C, Wu F, Liu X, Li T, Glauben R, Zhang Y, Nie G,He Y*, Qin Z*. Tie2 Expression on Macrophages Is Required for Blood Vessel Reconstruction and Tumor Relapse after Chemotherapy.Cancer Res. 76(23):6828-6838 (2016).

23. Park JS, Kim IK, Han S, Park I, Kim C, Bae J, Oh SJ, Lee S, Kim JH, Woo DC,He Y, Augustin HG, Kim I, Lee D, Koh GY. Normalization of Tumor Vessels by Tie2 Activation and Ang2 Inhibition Enhances Drug Delivery and Produces a Favorable Tumor Microenvironment.Cancer Cell30(6):953-967 (2016).

22. Han S, Lee SJ, Kim KE, Lee HS, Oh N, Park I, Ko E, Oh SJ, Lee YS, Kim D, Lee S, Lee DH, Lee KH, Chae SY, Lee JH, Kim SJ, Kim HC, Kim S, Kim SH, Kim C, Nakaoka Y,He Y, Augustin HG, Hu J, Song PH, Kim YI, Kim P, Kim I,Koh GY. Amelioration of sepsis by TIE2 activation-induced vascular protection.Sci Transl Med. 8(335):335ra55 (2016). doi: 10.1126/scitranslmed.aad9260.

21. Shen B#, Shang Z#, Wang B#, Zhang L#, Zhou F#, Li T, Chu M, Jiang H, Wang Y, Qiao T, Zhang J, Sun W, Kong X,He Y*. Genetic dissection of TIE pathway in lymphatic maturation and valve development.ATVB(Arterioscler Thromb Vasc Biol)34:1221-1230 (2014).

20. Zhang Y, Lu Y, Ma L, Cao X, Xiao J, Chen J, Jiao S, Gao Y, Liu C, Duan Z, Li D,He Y, Wei B, Wang H Activation of Vascular Endothelial Growth Factor Receptor-3 in Macrophages Restrains TLR4-NF-κB Signaling and Protects against Endotoxin Shock.Immunity. 40:501-514 (2014).

19. Xiong Y, Hu Z, Han X, Jiang B, Zhang R, Zhang X, Lu Y, Geng C, Li W,He Y, Huo Y, Shibuya M, Luo J. Hypertensive stretch regulates endothelial exocytosis of Weibel-Palade bodies through VEGF receptor 2 signaling pathways.Cell Res23:820-34 (2013).

18. Li T, Yang J, Zhou Q,He Y*. Molecular Regulation of Lymphangiogenesis in Development and Tumor Microenvironment.Cancer Microenviron. 5:249-260 (2012).

17. Lu Y, Xiong Y, Huo Y, Han J, Yang X, Zhang R, Zhu DS, Klein-Heßling S, Li J, Zhang X, Han X, Li Y, Shen B,He Y, Shibuya M, Feng GS, Luo J. Grb-2-associated binder 1 (Gab1) regulates postnatal ischemic and VEGF-induced angiogenesis through the protein kinase A-endothelial NOS pathway.Proc Natl Acad Sci U S A. 108:2957-2962 (2011).

16. Zhang L#, Zhou F#, Han W#, Shen B, Luo J, Shibuya M,He Y*. VEGFR-3 ligand-binding and kinase activity are required for lymphangiogenesis but not for angiogenesis.Cell Res20:1319-31 (2010)-Cover paper.

15. Zhou F#, Chang Z#, Zhang L#, Hong Y, Shen B, Wang B, Zhang F, Lu F, Tvorogov D, Alitalo K, Hemmings BA, Yang Z*,He Y*. Akt / Protein Kinase B is required for lymphatic network formation, remodeling and valve development.Am J Pathol177: 2124-2133 (2010).

14. Holopainen T#, Huang H#, Chen C#, Kim KE, Zhang L, Zhou F, Han W, Li C, Yu J, Wu J, Koh GY, Alitalo K*,He Y*. Angiopoietin-1 overexpression modulates vascular endothelium to facilitate tumor cell dissemination and metastasis establishment.Cancer Res69:4656-64 (2009).

13. Tammela T#,He Y#, Lyytikkä J, Jeltsch M, Markkanen J, Pajusola K, Ylä-Herttuala S, Alitalo K. Distinct Architecture of Lymphatic Vessels Induced by Chimeric Vascular Endothelial Growth Factor-C/Vascular Endothelial Growth Factor Heparin-Binding Domain Fusion Proteins.Circ Res100:1468-75 (2007).

12. Wirzenius M, Tammela M, Uutela M,He Y, Odorisio1 T, Zambruno1 G, Nagy JA, Dvorak HF, Ylä-Herttuala S, Shibuya M and Alitalo K. Distinct vascular endothelial growth factor signals for lymphatic vessel enlargement and sprouting.J Exp Med204:1431-40 (2007).

11.He Y, Rajantie I, Pajusola K, Jeltsch M, Holopainen T, Yla-Herttuala S, Harding T, Jooss K, Takahashi T, Alitalo K. VEGFR-3 mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels.Cancer Res65:4739-46(2005).

10. Lin J, Lalani AS, Harding TC, Gonzalez M, Wu WW, Luan B, Tu GH, Koprivnikar K, VanRoey MJ,He Y, Alitalo K, Jooss K. Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor.Cancer Res65:6901-9 (2005).

9. Bhardwaj S, Roy H, Karpanen T,He Y, Jauhiainen S, Hedman M, Alitalo K, Yla-Herttuala S. Periadventitial angiopoietin-1 gene transfer induces angiogenesis in rabbit carotid arteries.Gene Ther12:388-94 (2005).

8.He Y#, Rajantie I#, Ilmonen M, Makinen T, Karkkainen MJ, Haiko P, Salven P, Alitalo K. Preexisting lymphatic endothelium but not endothelial progenitor cells are essential for tumor lymphangiogenesis and lymphatic metastasis.Cancer Res64:3737-40 (2004).

7.He Y, Karpanen T and Alitalo K. Role of lymphangiogenic factors in lymphatic tumor metastasis.Biochim Biophys Acta（BBA Review Cancer）1654:3-12 (2004).

6. Uutela M, Wirzenius M, Paavonen K, Rajantie I,He Y, Karpanen T, Lohela M, Wiig H, Salven P, Pajusola K, Eriksson U, Alitalo K. PDGF-D induces macrophage recruitment, increased interstitial pressure and blood vessel maturation during angiogenesis.Blood104:3198-204 (2004).

5.He Y, Kozaki K, Karpanen T, Koshikawa K, Yla-Herttuala S, Takahashi T, Alitalo K. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling.J Natl Cancer Inst94:785-7 (2002).

4. Charnock-Jones DS, He Yand Smith SK. Angiogenesis and Vascular Endothelial Growth Factor (VEGF) in Reproduction. InThe New Angiotherapy(eds T-P D Fan & E C Kohn), pp.115-128 (2002). Humana Press.

3. Smith SK,He Y, Clark DE, Charnock-Jones DS. Angiogenic growth factor expression in placenta.Semin Perinatol24, 82-86 (2000).

2.He Y*, Smith SK, Day KA, Clark D, Licence DR, Charnock-Jones DS*. Alternative splicing of vascular endothelial growth factor (VEGF)-R1 (FLT-1) pre-mRNA is important for the regulation of VEGF activity.Mol Endocrinol13:537-545 (1999).

1. Clark DE, Smith SK,He Y, Day KA, Licence DR, Corps AN, and Charnock-Jones DS. A vascular endothelial growth factor antagonist is produced by the placenta and released into the maternal circulation.Biol Reprod59:1540-1548 (1998).